Cingulate Therapeutics (CTx) is a privately held biopharmaceutical company focused on the development of new products for the treatment of Central Nervous System and Neurobiological Disorders. Currently, CTx is developing two products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

The leadership team brings extensive expertise in ADHD, clinical trials, patient care, pharmaceutical development and new product commercialization.



Patient-Centric Approach

Improving the lives of patients is the cornerstone of our philosophy. Millions of children, adolescents and adults throughout the world struggle with symptoms and consequences of ADHD. Our goal is to provide patients with the most safe and effective treatments to lead productive and enjoyable lives.

Innovation at Our Core

CTx embraces innovation through cutting-edge technology, streamlined regulatory approach and demand for capital efficiency.

Overcome Long-standing Unmet Need

For decades, clinicians have sought to provide their ADHD patients with an ideal treatment that works quickly, provides appropriate duration and is safe and well tolerated. We aim to overcome this long-standing unmet need by providing new and exceptional treatment options for clinicians and patients.